/Regeneron%20Pharmaceuticals%2C%20Inc_%20pharmaceuticals%20by-%20okskaz%20via%20iStock.jpg)
Regeneron Pharmaceuticals, Inc. (REGN), with a market cap of $110.4 billion, is a leading biotechnology company based in Tarrytown, New York. Specializing in the discovery, development, and commercialization of treatments for various diseases, Regeneron focuses on diverse therapeutic areas such as ophthalmology, immunology, and infectious diseases.
Companies valued at $10 billion or more are generally considered “large-cap” stocks, and Regeneron Pharmaceuticals fits this criterion perfectly, exceeding the mark. Regeneron Pharmaceuticals stands out for its robust portfolio of innovative drugs targeting various serious medical conditions, including groundbreaking treatments like Eylea, Dupixent, and REGEN-COV2, the latter being a significant milestone in the fight against COVID-19.
